Pulmonary carcinoid tumors are uncommon neuroendocrine epithelial malignancies accounting for less than 1% of all lung cancers. They divide into two subcategories: typical carcinoids and atypical carcinoids. Typical carcinoids and atypical carcinoids are, respectively, low- and intermediate-grade neuroendocrine tumors. Approximately 80% of pulmonary carcinoids occur centrally, and 20% are peripheral. All bronchial carcinoids are malignant and have the potential to metastasize.
The mechanisms of carcinoid tumor development and progression are not clear, but some cases are postulated to develop in the setting of proliferating pulmonary neuroendocrine cells via diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) and tumorlets.
Some studies also showed a relationship of this tumor to smoking but the causation relationship is still not concrete. Air pollutants and certain chemicals have also shown a few risk factors among other studies. Some data shows a high incidence among the Whites and women as compared to men.
Carcinoid tumors comprise less than 1% of primary lung cancers. The mean age at presentation is about 50 years, but they can occur at any age from 5 to 90 years. Atypical carcinoids present approximately one decade later than typical carcinoids. About 8% develop in the second decade, making them the most common primary pulmonary tumor of childhood. Typical carcinoids are not correlated to tobacco smoking, although reports of atypical carcinoids are more frequent in smokers. Risk factors of carcinoids include having a family history of carcinoid tumors and carrying multiple endocrine neoplasia type 1 (MEN1) gene. This shows an inherited pattern of the tumor too.
Lung carcinoids are a part of the neuroendocrine tumors (NETs) that arise in the lungs. These NETs could show either a typical low grade, well-differentiated, slow-growing tumor or they may present as atypical high-grade, poorly differentiated carcinomas. However, the NETs share the capacity to synthesize neuropeptides and the presence of submicroscopic cytoplasmic dense-core.
Central carcinoid tumors are well-circumscribed, round to ovoid, and sessile or pedunculated. There is salt and pepper chromatin and moderate to abundant eosinophilic cytoplasm. They often fill the bronchial lumen. The tumors may grow between the cartilaginous plates into adjacent tissues. Carcinoids range in size from 0.5 to 9.5 cm. Atypical carcinoids are on average larger than typical carcinoids.
The growth patterns of carcinoid tumors suggest neuroendocrine differentiation. Organoid and trabecular patterns are most common; however, rosette formation, papillary growth, pseudo-glandular growth, and follicular growth may also be present. The tumor cells are usually uniform in appearance, with finely granular nuclear chromatin, inconspicuous nucleoli, and moderate to abundant eosinophilic cytoplasm. The stroma is classically highly vascularized, but extensive hyalinization, cartilage, or bone formation may be encountered. There are reports of stromal amyloid as well as the prominent mucinous stroma. Typical carcinoids are carcinoid tumors with less than 2 mitoses per 2mm2 and lacking necrosis. Atypical carcinoid generally shows the same range of histological features as typical carcinoid. The defining features are 2 to 10 mitoses per 2mm2 and/or necrosis. Necrosis is usually punctate. Mitoses counting should be in the area of highest mitotic activity in the fields filled with many viable tumor cells as possible and should also be per 2mm2 rather than ten high-power fields.
Immunohistochemistry may be a necessity for diagnosis, particularly on small biopsies. An antibody panel including chromogranin A, synaptophysin (both with cytoplasmic labeling), and CD56 (mostly decorating cell membranes) is the recommendation. However, none of these markers distinguish typical carcinoids from atypical carcinoids. Most carcinoids are also reactive for pan-cytokeratin antibodies. Some peripheral tumors also stain with TTF1, which is less specific. The Ki67 labeling index is valuable in biopsy or cytology samples, particularly with crush artifact where the mitotic index is difficult to assess, to avoid misdiagnosing carcinoid tumors as high neuroendocrine carcinomas.
Almost 25 percent of the people with lung carcinoid tumors may not present with any symptom of the disease. They may be diagnosed incidentally while being tested for another condition.
The most common presenting symptoms of bronchopulmonary carcinoid tumors are:
Since this tumor is primarily a carcinoid tumor, the patient's may present with symptoms of carcinoid syndrome:
Small carcinoids may be asymptomatic and only discovered, incidentally.
Most cases are endocrinologically silent at the clinical level. Clinical syndromes secondary to peptide production are uncommon, they include carcinoid syndrome, Cushing syndrome, and acromegaly.
Plasma chromogranin A measurement, blood count, electrolytes, liver, and kidney function are tests indicated in the diagnostic process and follow-up of carcinoids.
Specific tests are performed when symptoms suggesting hormonal secretion are present. They include:
Since lung carcinoids are usually centrally located and visible at endoscopic evaluation, bronchoscopy plays a significant role in their diagnosis. Bronchoscopic evaluation and biopsy is the gold standard for the diagnosis of pulmonary carcinoids; however, there is a risk of hemorrhage.
Carcinoids can are detectable on a standard chest x-ray in 40% of the cases. However, the gold standard for radiological detection of lung carcinoids is CT scan. On both, chest x-ray and CT scan, the mass is usually well-defined, round, and sometimes slightly lobulated. Calcification can occur in central carcinoid tumors. When bronchial involvement is present, secondary distal effects include atelectasis, bronchiectasis, and, hyperlucency on CT scan.
Fluorodeoxyglucose (FDG) positron emission tomography (PET) may distinguish carcinoid tumors from atypical carcinoids; this technique may be most helpful in discerning carcinoids from high-grade neuroendocrine tumors such as small cell or large cell neuroendocrine tumors. Carcinoids exhibit a low-to-moderate activity on PET scanning.
Octreotide single-photon emission CT and other novel imaging techniques such as gallium-labeled somatostatin analogs may be more sensitive at the detection of lung carcinoids. Imaging for somatostatin receptors using Indium-111-labeled-octreotide may increase the sensitivity for diagnosis, staging, and follow-up for recurrence.
The treatment of choice for patients with lung carcinoids is surgical resection. Extensive resections are necessary in the treatment of atypical carcinoids and cases of destruction of distal lung parenchyma. Lobectomy (sleeve or wedge resection) is the surgical technique of choice. Bronchoplastic procedures are often required since carcinoids often arise from main bronchi or lobar bronchi. A wedge resection is favored in peripheral carcinoids and is often sufficient.
There is no consensus on adjuvant therapy in pulmonary carcinoids. The National Comprehensive Cancer Network guidelines recommend adjuvant cisplatin and etoposide with or without radiation in stage III atypical carcinoids. The European Neuroendocrine Tumor Society advocates adjuvant treatment in atypical carcinoids with positive lymph nodes, but no adjuvant therapy for typical carcinoids.
The differential diagnoses of pulmonary carcinoids include:
In pulmonary carcinoid tumors, the classification system designates atypical carcinoids as intermediate grade. Atypical carcinoids are usually at a higher stage at presentation than typical carcinoids.
The distinction between atypical carcinoid and typical carcinoid is the most important prognostic factor. Atypical carcinoid has a worse prognosis than typical carcinoid. Atypical carcinoids are more likely to metastasize than typical carcinoids. Typical carcinoid tumors metastasize to hilar nodes in 10% to 15%. Distant metastases are less common. They occur in fewer than 3% of patients and involve the liver, lung, brain, adrenal or bone. For atypical carcinoid tumors, metastatic disease is present in 20% of patients. Age and nodal involvement are poor prognostic factors in patients with atypical carcinoids. Five-year survival rates for patients with typical carcinoids and atypical carcinoids are approximately 90% and 60% respectively.
|||Gosain R,Mukherjee S,Yendamuri SS,Iyer R, Management of Typical and Atypical Pulmonary Carcinoids Based on Different Established Guidelines. Cancers. 2018 Dec 12; [PubMed PMID: 30545054]|
|||Rosado de Christenson ML,Abbott GF,Kirejczyk WM,Galvin JR,Travis WD, Thoracic carcinoids: radiologic-pathologic correlation. Radiographics : a review publication of the Radiological Society of North America, Inc. 1999 May-Jun; [PubMed PMID: 10336200]|
|||Swarts DR,Ramaekers FC,Speel EJ, Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities. Biochimica et biophysica acta. 2012 Dec; [PubMed PMID: 22579738]|
|||Stankovic B,Aamodt H,Bjørhovde HAK,Müller E,Hammarström C,Brustugun OT,Helland Å,Øynebråten I,Corthay A, The immune microenvironment in typical carcinoid lung tumor, a brief report of four cases. Scandinavian journal of immunology. 2020 May 20; [PubMed PMID: 32433774]|
|||Hemminki K,Li X, Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer. 2001 Oct 15; [PubMed PMID: 11596039]|
|||Quaedvlieg PF,Visser O,Lamers CB,Janssen-Heijen ML,Taal BG, Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Annals of oncology : official journal of the European Society for Medical Oncology. 2001 Sep; [PubMed PMID: 11697843]|
|||Yao JC,Hassan M,Phan A,Dagohoy C,Leary C,Mares JE,Abdalla EK,Fleming JB,Vauthey JN,Rashid A,Evans DB, One hundred years after [PubMed PMID: 18565894]|
|||Kayser K,Kayser C,Rahn W,Bovin NV,Gabius HJ, Carcinoid tumors of the lung: immuno- and ligandohistochemistry, analysis of integrated optical density, syntactic structure analysis, clinical data, and prognosis of patients treated surgically. Journal of surgical oncology. 1996 Oct; [PubMed PMID: 8888802]|
|||Saber M,Ismail Y,Alieldin N,Loay I,El Zawahry M, Neuroendocrine tumors of the lung: A five-year retrospective experience of Egyptian NCI (2010-2014). Journal of the Egyptian National Cancer Institute. 2018 Dec; [PubMed PMID: 30470605]|
|||Rekhtman N, Neuroendocrine tumors of the lung: an update. Archives of pathology [PubMed PMID: 21043816]|
|||Zeng Y,Zhu Y,Ding Y,Xu L,Zhai B,Zhang X,Ge Q,Li J,Song Q,Li X,Zhang Z, Analysis of lung biopsies using the 2015 WHO criteria and detection of sensitizing mutations--a single-institution experience of 5032 cases. Diagnostic pathology. 2020 May 19; [PubMed PMID: 32429938]|
|||Ferolla P, Medical treatment of advanced thoracic neuroendocrine tumors. Thoracic surgery clinics. 2014 Aug; [PubMed PMID: 25065936]|
|||Caplin ME,Baudin E,Ferolla P,Filosso P,Garcia-Yuste M,Lim E,Oberg K,Pelosi G,Perren A,Rossi RE,Travis WD, Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Aug; [PubMed PMID: 25646366]|
|||Filosso PL,Rena O,Donati G,Casadio C,Ruffini E,Papalia E,Oliaro A,Maggi G, Bronchial carcinoid tumors: surgical management and long-term outcome. The Journal of thoracic and cardiovascular surgery. 2002 Feb; [PubMed PMID: 11828290]|
|||Queiroz RM,Santana DBF,Nastri Filho R,Landell GAM,Félix PR,Valentin MVN, Endobronchial carcinoid tumor: Radiological findings of a clinical case. Revista da Associacao Medica Brasileira (1992). 2018 Jan; [PubMed PMID: 29561937]|
|||Daniels CE,Lowe VJ,Aubry MC,Allen MS,Jett JR, The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. Chest. 2007 Jan; [PubMed PMID: 17218584]|
|||Venkitaraman B,Karunanithi S,Kumar A,Khilnani GC,Kumar R, Role of 68Ga-DOTATOC PET/CT in initial evaluation of patients with suspected bronchopulmonary carcinoid. European journal of nuclear medicine and molecular imaging. 2014 May; [PubMed PMID: 24435773]|
|||Erasmus JJ,McAdams HP,Patz EF Jr,Coleman RE,Ahuja V,Goodman PC, Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR. American journal of roentgenology. 1998 May; [PubMed PMID: 9574618]|
|||Lim E,Yap YK,De Stavola BL,Nicholson AG,Goldstraw P, The impact of stage and cell type on the prognosis of pulmonary neuroendocrine tumors. The Journal of thoracic and cardiovascular surgery. 2005 Oct; [PubMed PMID: 16214506]|
|||Naalsund A,Rostad H,Strøm EH,Lund MB,Strand TE, Carcinoid lung tumors--incidence, treatment and outcomes: a population-based study. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 2011 Apr; [PubMed PMID: 20888248]|
|||Crocetti E,Paci E, Malignant carcinoids in the USA, SEER 1992-1999. An epidemiological study with 6830 cases. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP). 2003 Jun; [PubMed PMID: 12771556]|
|||Steuer CE,Behera M,Kim S,Chen Z,Saba NF,Pillai RN,Owonikoko TK,Khuri FR,Ramalingam SS, Atypical carcinoid tumor of the lung: a surveillance, epidemiology, and end results database analysis. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015 Mar; [PubMed PMID: 25371080]|